Neuro-Oncology Branch - Publications

• Purow BW, Haque RM, Noel MW, Qin S, Burdick MJ, Jeongwu L, Dragan M, Tilak S, Pastorino S, Mikolaenko I, Eberhart CG, Fine HA (InPress) Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation, Cancer Research.

• Fine HA. (InPress) Targeted therapies for malignant gliomas, Nature Review Drug Discovery, .

• Anderson SA, Glod J, Arbab As, Noel N. Asharia P, Fine HA, Frank JA. (2005) . Non-invasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. , Blood 105, 420-425.

• Chen W, Lee J, Cho S. Fine HA. (2004) . Proteosome-mediated destruction of the cyclin A/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. , Cancer Research 64(11), 3949-57.

• Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, Fine HA. (2004) Agents with selective estrogen receptor modulator activity induce apoptosis in vitro and in vivo in estrogen receptor-negative glioma cells., Cancer Research 64, 9115-9123.

• Sun L, Lee J, Fine HA. (2004) Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury, J Clin Invest . 113(9), 1364-1374.

• Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. (2003) . A phase II trial of Thalidomide and BCNU for patients with recurrent high grade gliomas., J. Clin Oncol 21(12), 2299-304.

• Ferrari N, Glod J, Lee J, Kobiler D, Fine HA (2003) Bone marrow-derived, endothelial progenitor-like cells as angiogenesis�selective gene targeting vectors, Gene Therapy 10(8), 647-56.

• Lee J, Elkahloun AG, Messina SA, Ferrari N, Xi D, Smith CL, Cooper R Jr, Albert PS, Fine HA. (2003) . Cellular and genetic characterization of human adult bone-marrow-derived neural stem-like cells: a potential anti-glioma cellular vector. , Cancer Res. 63(24), 8877-89.

• Buetow KH, Klausner RD, Fine HA, Kaplan R, Singer DS, Strausberg RL. (2002) Cancer molecular analysis project: weaving a rich cancer research tapestry, Cancer Cell 1, 315-18.

• Lee J, Hampl M, Albert P, Fine HA (2002) Anti-tumor activity and prolonged expression from a TRAIL-expressing adenoviral vector, Neoplasia 4, 312-323.

• Hampl M, Toshihide T, Albert PS, Lee J, Ferrari N, Fine HA. (2001) Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites, Human Gene Therapy 12, 1713-1729.

• Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG, Fine HA, Black PM, Loeffler JS, Linet MS (2001) Cellular-telephone use and brain tumors. , N Engl J Med. . 344(2), 79-86.

• Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black, PM, Kaplan R, Pluda JM, Yung WK. (2000) A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high grade gliomas. , J Clin Onc 18(4), 708-715.

• Tanaka, T, Cao Y, Folkman, J, Fine HA. (1998) Viral vector-targeted anti-angiogenic gene therapy utilizing an angiostatin cDNA. , Cancer Research 58(15), 3362-3369.

• Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA (1998) Immune parameters affecting adenoviral vector gene therapy in the brain., J Neurovirol 4(2) , 194-203.

• Fine HA, Wen, PY, Robertson M, O�Neil A, Kowal J, Loeffler JS, Black PM. (1997) A phase I trial of a new recombinant human interferon Beta (BG9015) for the treatment of patients with recurrent gliomas, Clin Cancer Res 3(3), 381-387.

• Tanaka T, Manome Y, Wen PY, Kufe DW, Fine HA. (1997) Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. , Nature Medicine. 3(4) , 437-42.

• Parr MJ, Manome Y, Tanaka T, Wen P, Kufe D, Kaelin WG, Fine HA. (1997) Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector, Nature Medicine. 3(10), 1145-1149.

• Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell B.S., Kufe DW, Fine HA. (1996) . Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. , Nature Medicine 2(5), 567-573.